Ipsen to Acquire Memo Therapeutics in Deal Worth Over €700 Million, Securing Phase II BK Polyomavirus Antibody Potravitug
核心洞察
Ipsen has entered into a definitive agreement to acquire Memo Therapeutics (搜索) in a transaction potentially exceeding €700 million, expanding its rare disease portfolio.
The acquisition centers on potravitug, a Phase II anti-BK polyomavirus (搜索) antibody targeting BK polyomavirus-associated nephropathy (搜索) in renal transplant patients.
Memo shareholders will receive €200 million upfront, with additional payments tied to development, regulatory approval, and sales-based milestones.
French pharmaceutical company Ipsen has entered into a definitive agreement to acquire Memo Therapeutics (搜索) in a transaction that could be worth over €700 million, the company announced. The deal is designed to expand Ipsen's rare disease portfolio and is centered on potravitug, a Phase II clinical-stage antibody targeting the BK polyomavirus (搜索) (BKPyV).
Under the terms of the agreement, Memo shareholders will receive an upfront payment of €200 million on a cash-free and debt-free basis at closing, along with deferred payments contingent upon the achievement of specified development, regulatory approval, and sales-based milestones.
Clinical Focus: BK Polyomavirus-Associated Nephropathy (搜索)
The anticipated acquisition is focused on potravitug, an antibody directed against BK polyomavirus (搜索). BK polyomavirus-associated nephropathy (搜索) (BKPyVAN) represents a serious and frequent clinical complication in renal transplanted patients that can lead to graft loss and transplant failure. Currently, no approved therapies specifically target this condition, underscoring the significant unmet medical need in the transplant population.
Regulatory Designations
Potravitug has secured two important regulatory milestones. The U.S. Food and Drug Administration (FDA) granted the therapy Fast Track designation in May 2023, a status intended to expedite the development and review of drugs addressing serious conditions with unmet medical needs. Additionally, the European Union awarded potravitug Orphan Drug designation in December 2025, providing incentives for the development of therapies for rare diseases.
Transaction Structure and Timeline
As a condition precedent to closing the transaction, Memo Therapeutics (搜索)' assets and employees not related to potravitug will be transferred to a newly incorporated company, Memorises Bio, which will be retained by Memo Therapeutics' existing shareholders. This structure allows Ipsen to focus exclusively on the potravitug program while Memo's legacy shareholders retain other pipeline assets.
The transaction is expected to close during the third quarter of 2026, subject to the fulfillment of customary closing conditions. Ipsen noted that the impact of this proposed mid-stage acquisition is factored into the company's current full-year guidance.
Strategic Rationale
The acquisition aligns with Ipsen's strategic focus on rare diseases, adding a mid-stage clinical asset with established regulatory designations to its pipeline. By targeting BK polyomavirus-associated nephropathy (搜索), Ipsen positions itself to address a complication for which no approved pharmacological intervention currently exists, potentially offering a first-in-class therapeutic option for renal transplant patients at risk of graft failure.